Biotech Values

[AlpineBV_Miller]

Scher's comments about the CVA are also specious.

1. He voted that they didn't make a difference to the judgement that Provenge was safe.
2. There is no evidence that CVA is a side effect of Provenge seperate from being a "side effect" of living longer in this patient population.
3. Toss this patient population into a risk calculator for CVAs and you'll get the same percentages as you get in the Provenge arm.
4. There were two cardiovascular/cerebrovacular immunology experts on the panel and they were perfectly satisfied with a monitoring program.